Abigail Beaney

Manchester

Pharmaceutical Reporter at Clinical Trials Arena

Pharmaceutical Reporter @trialsarena 📰

Articles

BioOrbit eyes 2026 for pre-clinical trials of space manufactured protein crystals

1 week ago | pharmaceutical-technology.com | Abigail Beaney

CEO Dr Katie King said that the microgravity environment enables the production of purer crystals, resulting in more concentrated therapies. The ‘space factory’ will likely be within a satellite, King explained at HLTH Europe. Image credit: Rini. com/ Shutterstock. BioOrbit aims to kick off pre-clinical trials to study protein crystals for monoclonal antibodies (mAbs) produced in a pharmaceutical factory in space in 2026.
NHS England chair suggests England can learn from European health schemes

1 week ago | pharmaceutical-technology.com | Abigail Beaney

Penny Dash shared her views during a fireside discussion at HLTH Europe in Amsterdam. NHS England chair Penny Dash speaking with The Sunday Times’ health editor Shaun Lintern. Image credit: Abigail Beaney / GlobalData. With the 10-year Health Plan on the horizon, the NHS could learn some tricks from France, Germany and the Nordics.
Novo Nordisk seeks digital health partners to boost GLP-1RA weight loss outcomes

1 week ago | pharmaceutical-technology.com | Abigail Beaney

Novo Nordisk aims to collaborate with mobile app developers as well as pharmacies and telehealth providers. Anne Cathrine Fleischer, vice president of Global Obesity Consumer Engagement and New Business Models at Novo Nordisk, announced the platform at HLTH Europe.
Genomics to roll out predictive clinical test across UK

1 week ago | pharmaceutical-technology.com | Abigail Beaney

The test is currently available in private healthcare facilities but there are hopes it may be adopted by the NHS. Genomics CEO Professor Sir Peter Donnelly with Justin Ash, CEO of Spire Healthcare. Image credit: Genomics. Oxford-based company Genomics is launching its Health Insights test across the UK, which will be used to predict and prevent diseases.
European pharma needs scalable models to succeed in US

1 week ago | pharmaceutical-technology.com | Abigail Beaney

HLTH Europe hosted discussions on the challenges European companies face while entering the US market. With potential tariffs and other changes in the US market, it is important for European companies to show they have a scalable model if they want to break into the market. Image credit: Tomas Ragina / Shutterstock.
Novo Nordisk ramps up obesity fight, advances amycretin to Phase III

2 weeks ago | clinicaltrialsarena.com | Abigail Beaney

Novo Nordisk is progressing both subcutaneous and oral versions of amycretin into Phase III trials for patients with obesity and who are overweight. Following a positive end-of-Phase II meeting, Novo Nordisk shared that regulatory authorities have approved the therapy to proceed. The company plans to initiate the trial in adults who are overweight or with obesity in Q1 2026.
Wes Streeting: £29bn NHS boost ‘substantial’ but reform still needed

2 weeks ago | pharmaceutical-technology.com | Abigail Beaney

The health secretary addressed NHS employees a day after the £29bn NHS funding was announced. Wes Streeting spoke about the funding, the 10-year plan and other difficulties the NHS has been facing in recent years. Image credit: Abigail Beaney / GlobalData A £29bn investment into the National Health System (NHS) is ‘substantial’, but reform of the system is essential to ‘fix the NHS’, says UK Secretary of Health and Social Care Wes Streeting MP.
ASCO25: Novartis hopes Scemblix becomes new standard for CML-CP

3 weeks ago | clinicaltrialsarena.com | Abigail Beaney

Novartis is hoping that Scemblix (asciminib) will become the physician’s first choice of therapy for chronic myeloid leukaemia in chronic phase (CML-CP) after it has shown to be more tolerable than the standard of care (SOC) in a Phase IIIb trial. Scemblix is a first-in-class STAMP inhibitor which received accelerated approval by the US Food and Drug Administration (FDA) in 2021 in previously treated CML in adult patients.
ASCO25: MSD’s KRAS G12C drug shows early promise in Phase I

3 weeks ago | pharmaceutical-technology.com | Abigail Beaney

MSD is also investigating the KRAS G12C inhibitor in two Phase III trials. MSD investigated the KRAS G12C inhibitor in patients with solid tumours, including advanced colorectal cancer and non-small cell lung cancer. Image credit: Shutterstock / Atmosphere1. MSD’s investigational KRAS G12C inhibitor has shown signs of anti-tumour activity when used both alone and in combination with other oncology drugs.
ASCO25: Merck KGaA’s ADC shows safety and tolerability in colorectal cancer trial

4 weeks ago | clinicaltrialsarena.com | Abigail Beaney

Merck KGaA’s antibody-drug conjugate (ADC), precemtabart tocentecan, has shown to be safe and tolerable in a Phase Ib trial. The ongoing PROCEADE-CRC-01 study (NCT05464030) is investigating the dose, safety and tolerability of intravenous (IV) precemtabart tocentecan in approximately 200 patients with metastatic colorectal cancer (mCRC). The study is also looking at early signs of efficacy. Two doses of the drug, 2.4mg/kg and 2.8mg/kg, are being investigated, with patients dosed every three weeks.